GENEURO SA has a total of 90 patent applications. It increased the IP activity by 180.0%. Its first patent ever was published in 2007. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are CHEN LIEPING, PHARMAGAP INC and NEUTEC PHARMA PLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 10 | |
#2 | EPO (European Patent Office) | 9 | |
#3 | WIPO (World Intellectual Property Organization) | 7 | |
#4 | Israel | 6 | |
#5 | Australia | 5 | |
#6 | China | 5 | |
#7 | Mexico | 5 | |
#8 | Brazil | 4 | |
#9 | Canada | 4 | |
#10 | EAPO (Eurasian Patent Organization) | 4 | |
#11 | Republic of Korea | 4 | |
#12 | Hong Kong | 3 | |
#13 | Hungary | 3 | |
#14 | Japan | 3 | |
#15 | South Africa | 3 | |
#16 | Argentina | 2 | |
#17 | Ecuador | 2 | |
#18 | Singapore | 2 | |
#19 | Taiwan | 2 | |
#20 | Ukraine | 2 | |
#21 | France | 1 | |
#22 | India | 1 | |
#23 | New Zealand | 1 | |
#24 | Serbia | 1 | |
#25 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Microorganisms | |
#5 | Measuring microorganism processes | |
#6 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Perron Herve | 44 |
#2 | Madeira Alexandra | 35 |
#3 | Medina Julie | 27 |
#4 | Perron Hervé | 24 |
#5 | Firouzi Reza | 19 |
#6 | Faucard Raphaël | 17 |
#7 | Faucard Raphael | 17 |
#8 | Bernard Corinne | 17 |
#9 | Lang Alois Bernhardt | 17 |
#10 | Lang Alois | 16 |
Publication | Filing date | Title |
---|---|---|
WO2019201908A1 | Method for the detection of the soluble hydrophilic oligomeric form of herv-w envelope protein | |
EP3351265A1 | Anti-herv-k envelope antibody and uses thereof | |
EP2949342A1 | Antiretroviral drug targeting human endogenous retrovirus | |
AU2013326552A1 | Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein | |
EP2315777A1 | Therapeutic use of specific ligand in msrv associated diseases | |
EP2117594A2 | Pharmaceutical composition containing antibodies directed against the herv-w envelope |